Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia

BMC Cancer

Eliana Abdelhay¹  Marcelo F Santiago³  Bárbara Du Rocher¹  Daniela Salles²  Stephany Corrêa¹  André L Mencalha⁴ 

[1]Bone Marrow Transplantation Unit (CEMO), National Cancer Institute (INCA), Rio de Janeiro, Brazil

[2]Department of Obstetrics and Gynecology, University of Ulm, Prittwitzstrasse 43, Ulm D-89075, Germany

[3]Institute of Biophysics Carlos Chagas Filho (IBCCF), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil

[4]Departamento de Biofísica e Biometria, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro, 28 Avenida de Setembro, 87 Fundos – 4 Andar, Vila Isabel, Rio de Janeiro 20551-030, Brazil

关键词: Imatinib mesylate;    STATIP1;    BCR-ABL;    Chronic myeloid leukemia;    STAT3;   

Others  :  1118021
DOI  :  10.1186/1471-2407-14-866

 received in 2014-09-17, accepted in 2014-11-11,  发布年份 2014

【 摘 要 】

Background

Signal transducer and activator of transcription 3 (STAT3) is an important transcriptional factor frequently associated with the proliferation and survival of a large number of distinct cancer types. However, the signaling pathways and mechanisms that regulate STAT3 activation remain to be elucidated.

Methods

In this study we took advantage of existing cellular models for chronic myeloid leukemia resistance, western blot, in vitro signaling, real time PCR, flow cytometry approaches for cell cycle and apoptosis evaluation and siRNA assay in order to investigate the possible relationship between STATIP1, STAT3 and CML resistance.

Results

Here, we report the characterization of STAT3 protein regulation by STAT3-interacting protein (STATIP1) in the leukemia cell line K562, which demonstrates constitutive BCR-ABL TK activity. K562 cells exhibit high levels of phosphorylated STAT3 accumulated in the nucleus and enhanced BCR-ABL-dependent STAT3 transcriptional activity. Moreover, we demonstrate that STATIP1 is not involved in either BCR-ABL or STAT3 signaling but that STATIP1 is involved in the down-regulation of STAT3 transcription levels; STATIP1-depleted K562 cells display increased proliferation and increased levels of the anti-apoptosis STAT3 target genes CCND1 and BCL-XL, respectively. Furthermore, we demonstrated that Lucena, an Imatinib (IM)-resistant cell line, exhibits lower STATIP1 mRNA levels and undergoes apoptosis/cell cycle arrest in response to STAT3 inhibition together with IM treatment. We provide evidence that STATIP1 siRNA could confer therapy resistance in the K562 cells. Moreover, analysis of CML patients showed an inverse expression of STAIP1 and STAT3 mRNA levels, ratifying that IM-resistant patients present low STATIP1/high STAT3 mRNA levels.

Conclusions

Our data suggest that STATIP1 may be a negative regulator of STAT3 and demonstrate its involvement in IM therapy resistance in CML.

【 授权许可】

   
2014 Mencalha et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Garcia R, Jove R: Activation of STAT transcription factors in oncogenic tyrosine kinase signalling. J Biomed Sci 1998, 5:79-85.
• [2]Turkson J, Bowman T, Garcia R, Caldenhoven E, de Groot RP, Jove R: Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 1998, 18:2545-2552.
• [3]Coppo P, Dusanter-Fourt I, Millot G, Nogueira MM, Dugray A, Bonnet ML, Mitjavila-Garcia MT, Le Pesteur D, Guilhot F, Vainchenker W, Sainteny F, Turhan AG: Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Oncogene 2003, 22:4102-4110.
• [4]Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS: Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the Interleukin 6/gp130 cytokine system. Cancer Res 2003, 63:2948-2956.
• [5]Coppo P, Flamant S, De Mas V, Jarrier P, Guillier M, Bonnet ML, Lacout C, Guilhot F, Vainchenker W, Turhan AG: BCR-ABL activates STAT3 via JAK end MEK pathways in human cells. Br J Haematol 2006, 134:171-179.
• [6]Rawlings JS, Rosler KM, Harrison DA: The JAK/STAT signaling pathway. J Cell Sci 2004, 117:1281-1283.
• [7]Bromberg J, Darnell JE Jr: The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19:2468-2473.
• [8]Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K, Hibi M, Hirano T: STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 1999, 189:63-73.
• [9]Hirano T, Ishihara K, Hibi M: Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000, 20:2548-2556.
• [10]Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, Mansour M, Xu LM, Costanzo C, Cheng JQ, Wang LH: Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem 2008, 283:14665-14673.
• [11]Cambier N, Chopra R, Strasser A, Metcalf D, Elefanty AG: BCR-ABL activates pathways medianting cytokine independence and protection against apoptosis in murine haematopoietic cells in a dose-dependent manner. Oncogene 1998, 16:335-348.
• [12]Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA: JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004, 18:189-218.
• [13]Steelman LS, Abrams SL, Whelan J, Bertrand FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A, Lunghi P, Bonati A, Martelli AM, McCubrey JA: Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008, 22:686-707.
• [14]McLaughlin J, Chianese E, Witte ON: In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci U S A 1987, 84:6558-6562.
• [15]Spiekermann K, Biethahn S, Wilde S, Hiddemann W, Alves F: Constitutive activation of STAT transcription factors in acute myelogenous leukaemia. Eur J Haematol 2001, 67:63-71.
• [16]Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W: Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells. Exp Hematol 2002, 30:262-271.
• [17]Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA: STAT3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. Mol Cancer Ther 2008, 7:3169-3175.
• [18]Chana TK, Lia K, Liua SL, Chua KH, Toha M, Xie WD: Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukaemia cell line K562. Cancer Lett 2009, 289:46-59.
• [19]Jia HY, Wu JX, Zhu XF, Chen JM, Yang SP, Yan HJ, Tan L, Zeng YX, Huang W: ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells. Leuk Res 2009, 33:1512-1519.
• [20]Espert L, Dusanter-Fourt I, Chelbi-Alix MK: Negative regulation of the JAK/STAT: pathway implication in tumorigenesis. Bull Cancer 2005, 92:845-857.
• [21]Yang CH, Shi W, Basu L, Murti A, Constantinescu SN, Blatt L, Croze E, Mullersman JE, Pfeffer LM: Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor. J Biol Chem 1996, 271:8057-8061.
• [22]Nakayama K, Kim KW, Miyajima A: A novel nuclear zinc finger protein EZI enhances nuclear retention and transactivation of STAT3. EMBO J 2002, 21:6174-6184.
• [23]Sato N, Kawai T, Sugiyama K, Muromoto R, Imoto S, Sekine Y, Ishida M, Akira S, Matsuda T: Physical and functional interactions between STAT3 and ZIP kinase. Int Immunol 2005, 17:1543-1552.
• [24]Lufei C, Koh TH, Uchida T, Cao X: Pin1 is required for the Ser727 phosphorylation-dependent Stat3 activity. Oncogene 2007, 26:7656-7664.
• [25]Zhang T, Ma J, Cao X: Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling. Biochem J 2003, 376:457-464.
• [26]Yamashina K, Yamamoto H, Chayama K, Nakajima K, Kikuchi A: Suppression of STAT3 activity by Duplin, which is a negative regulator of the Wnt signal. J Biochem 2006, 139:305-314.
• [27]Muromoto R, Nakao K, Watanabe T, Sato N, Sekine Y, Sugiyama K, Oritani K, Shimoda K, Matsuda T: Physical and functional interactions between Daxx and STAT3. Oncogene 2006, 25:2131-2136.
• [28]Wu Z, Zhang X, Yang J, Wu G, Zhang Y, Yuan Y, Jin C, Chang Z, Wang J, Yang X, He F: Nuclear protein IkappaB-zeta inhibits the activity of STAT3. Biochem Biophys Res Commun 2009, 387:348-352.
• [29]Collum RG, Brutsaert S, Lee G, Schindler C: A Stat3-interacting protein (StIP1) regulates cytokine signal transduction. Proc Natl Acad Sci 2000, 97:10120-10125.
• [30]Smith TF, Gaitatzes C, Saxena K, Neer EJ: The WD repeat: a common architecture for diverse functions. Trends Biochem Sci 1999, 24:181-185.
• [31]Rumjanek VM, Trindade GS, Wagner-Souza K, de-Oliveira MC, Marques-Santos LF, Maia RC, Capella MA: Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1. An Acad Bras Cienc 2001, 73:57-69.
• [32]Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108.
• [33]Nicoletti I, Migliorati G, Pagliaccil MC, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991, 139:271-279.
• [34]Benekli M, Baer MR, Baumann H, Wetzler M: Signal transducer and activator of transcription proteins in leukemias. Blood 2003, 15:2940-2954.
• [35]Mencalha AL, Du Rocher B, Salles D, Binato R, Abdelhay E: LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate. Cancer Chemother Pharmacol 2010, 65:1039-1046.
• [36]Frank DA: STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007, 251:199-210.
• [37]Ichiba M, Nakajima K, Yamanaka Y, Kiuchi N, Hirano T: Autoregulation of the Stat3 gene through cooperation with a cAMP-responsive element-binding protein. J Biol Chem 1998, 273:6132-6138.
• [38]Tsuruma R, Ohbayashi N, Kamitani S, Ikeda O, Sato N, Muromoto R, Sekine Y, Oritani K, Matsuda T: Physical and functional interactions between STAT3 and KAP1. Oncogene 2008, 27:3054-3059.
• [39]Corrêa S, Pizzatti L, Du Rocher B, Mencalha A, Pinto D, Abdelhay E: A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line. Proteome Sci 2012, 10:23. BioMed Central Full Text
• [40]Hawkes NA, Otero G, Winkler GS, Marshall N, Dahmus ME, Krappmann D, Scheidereit C, Thomas CL, Schiavo G, Erdjument-Bromage H, Tempst P, Svejstrup JQ: Purification and characterization of the human elongator complex. J Biol Chem 2002, 277:3047-3055.
• [41]Ma LD, Zhou M, Wen SH, Ni C, Jiang LJ, Fan J, Xia L: Effects of STAT3 silencing on fate of chronic myelogenous leukemia K562 cells. Leuk Lymphoma 2010, 51:1326-1336.
• [42]Bourguignon LYW, Peyrollier K, Xia W, Gilad E: Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 2008, 283:17635-1751.
• [43]Zhang X, Xiao W, Wang L, Tian Z, Zhang J: Deactivation of signal transducer and activator of transcription 3 reverses chemotherapeutics resistance of leukemia cells via down-regulating P-gp. PLoS One 2011, 6:20965-20969.